{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:40:34Z","timestamp":1772692834932,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81602903"],"award-info":[{"award-number":["81602903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"State Key Laboratory for Infectious Disease Prevention and Control","award":["2015SKLID502"],"award-info":[{"award-number":["2015SKLID502"]}]},{"name":"Medical Scientific Research Foundation of Hubei Province, China","award":["JX6B23"],"award-info":[{"award-number":["JX6B23"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.02.112","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T05:10:55Z","timestamp":1520485855000},"page":"1983-1989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China"],"prefix":"10.1016","volume":"36","author":[{"given":"Bingqing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.112_b0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.112_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.112_b0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.112_b0020","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/14712598.2013.812629","article-title":"Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review","volume":"13","author":"Ghanem","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.112_b0025","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.112_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jinf.2014.07.022","article-title":"Clonal characteristics of invasive Neisseria meningitidis following initiation of an A + C vaccination program in China, 2005\u20132012","volume":"70","author":"Zhou","year":"2015","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2018.02.112_b0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.112_b0045","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.112_b0055","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"issue":"16","key":"10.1016\/j.vaccine.2018.02.112_b0060","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.112_b0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1179\/2047773213Y.0000000119","article-title":"An epidemiological review of changes in meningococcal biology during the last 100 years","volume":"107","author":"Abio","year":"2013","journal-title":"Pathog Glob Health"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.112_b0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.vaccine.2014.10.072","article-title":"Prevalence of meningococcal meningitis in China from 2005 to 2010","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.02.112_b0075","first-page":"300","article-title":"Epidemiological surveillance and prophylaxis of epidemic cerebrospinal meningitis","volume":"5","author":"Hu","year":"2001","journal-title":"Chin J Vaccine Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2018.02.112_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/016164110X12644252260754","article-title":"Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention","volume":"32","author":"Safadi","year":"2010","journal-title":"Neurol Res"},{"issue":"12 Suppl","key":"10.1016\/j.vaccine.2018.02.112_b0085","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"31","key":"10.1016\/j.vaccine.2018.02.112_b0090","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/S0264-410X(01)00205-5","article-title":"Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6\u20138 October, 2000","volume":"19","author":"Cartwright","year":"2001","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.112_b0095","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"9508","key":"10.1016\/j.vaccine.2018.02.112_b0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(06)68141-5","article-title":"Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China","volume":"367","author":"Shao","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.112_b0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3201\/eid1602.090901","article-title":"Neisseria meningitidis serogroup W135, China","volume":"16","author":"Shao","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0110","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3201\/eid2106.140687","article-title":"Sequence type 4821 clonal complex serogroup B Neisseria meningitidis in China, 1978\u20132013","volume":"21","author":"Zhu","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0115","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0120","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.112_b0125","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2008.12.052","article-title":"Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease","volume":"27","author":"Jacobsson","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.112_b0130","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/IAI.72.7.4217-4223.2004","article-title":"NadA diversity and carriage in Neisseria meningitidis","volume":"72","author":"Comanducci","year":"2004","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.112_b0135","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.02.112_b0140","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/1471-2164-11-652","article-title":"Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020\u201306","volume":"11","author":"Bennett","year":"2010","journal-title":"BMC Genom"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0145","doi-asserted-by":"crossref","first-page":"e0158315","DOI":"10.1371\/journal.pone.0158315","article-title":"Temporal changes in BEXSERO(R) antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia","volume":"11","author":"Mowlaboccus","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.02.112_b0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12866-015-0469-6","article-title":"Characterization of invasive Neisseria meningitidis strains from Quebec, Canada, during a period of increased serogroup B disease, 2009\u20132013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets","volume":"15","author":"Law","year":"2015","journal-title":"BMC Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.02.112_b0155","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/651505","article-title":"Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era\u2013United States, 2000\u20132005","volume":"201","author":"Harrison","year":"2010","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1469-0691.2008.01977.x","article-title":"Genetic characteristics of serogroup A meningococci circulating in China, 1956\u20132005","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2018.02.112_b0165","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1099\/jmm.0.47263-0","article-title":"Molecular characterization of serogroup C Neisseria meningitidis isolated in China","volume":"56","author":"Zhang","year":"2007","journal-title":"J Med Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.112_b0170","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"issue":"7","key":"10.1016\/j.vaccine.2018.02.112_b0175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.112_b0180","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies","volume":"79","author":"Seib","year":"2011","journal-title":"Infect Immun"},{"issue":"37","key":"10.1016\/j.vaccine.2018.02.112_b0185","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2018.02.112_b0190","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2018.02.112_b0195","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2018.02.112_b0200","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2018.02.112_b0205","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2018.02.112_b0210","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.112_b0215","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"10.1016\/j.vaccine.2018.02.112_b0220","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2018.02.112_b0225","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups","volume":"32","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18303220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T16:17:38Z","timestamp":1660580258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18303220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X18303220"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.112","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}